Nuclear Receptors and Drug Drug Interactions: How to Better Understand Potential Toxicity

Drug-drug interactions (DDI) resulting in adverse outcomes cause approximately 3% of all hospitalizations annually in the United States. This costs the health care system over a billion dollars. Fortunately, many aspects of DDI are predictable based on the increasing understanding of the mechanisms of altered absorption, distribution, metabolism and excretion (ADME). Watch this webinar to learn about various drug screening assays that are available for identifying potential DDI in vitro. Drug screening assays improve drug safety and allow for the prioritization of drug candidates. PXR and several other important xenobiotic sensing and drug metabolism inducing systems will be described. These include Aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), Farnesoid X Receptor (FXR) and Nuclear factor-erythroid factor 2-related factor 2 (Nrf2).